vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday

Key Points

• vTv Therapeutics is set to report results before the market opens on Thursday, March 19, with analysts projecting EPS of ($0.98); the company last reported ($0.58) EPS for the quarter, beating prior consensus of ($1.09) by $0.51.
• The stock trades around $35.10 (52‑week range $14–$44) with a market cap of $138.3M, and analysts hold a consensus rating of Moderate Buy with a $55.25 average target.
• vTv is a clinical‑stage biopharma focused on oral small‑molecule therapies, with lead candidate azeliragon having completed Phase II/III evaluation in early‑stage Alzheimer’s disease.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) is projected to post its results before the market opens on Thursday, March 19th. Analysts expect vTv Therapeutics to post earnings of ($0.98) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

vTv Therapeutics Price Performance

Shares of NASDAQ VTVT opened at $35.10 on Thursday. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The business's 50-day moving average price is $36.18 and its two-hundred day moving average price is $29.26. The company has a market capitalization of $138.29 million, a P/E ratio of -10.48 and a beta of 0.44.

Analyst Ratings Changes

VTVT has been the subject of several recent research reports. Roth Mkm began coverage on vTv Therapeutics in a research note on Thursday, January 22nd. They issued a "buy" rating and a $58.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of vTv Therapeutics in a research report on Monday, December 29th. TD Cowen began coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They issued a "buy" rating for the company. Wall Street Zen upgraded shares of vTv Therapeutics to a "sell" rating in a research note on Saturday, December 27th. Finally, BTIG Research restated a "buy" rating and set a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $55.25.

Institutional Investors Weigh In On vTv Therapeutics

Large investors have recently added to or reduced their stakes in the stock. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter worth $731,000. Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $221,000. Institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.